Hemoglobin
molecules are too large to pass through capillary walls.
血红蛋白分子过大，以至于不能通过毛细血管壁。
A water molecule is made of two hydrogen atoms and one oxygen atom.
水分子由两个氢原子和一个氧原子构成。
Molecules are made up of atoms.
分子由原子组成。
RLT works by combining a targeting molecule — the ligand — that binds to a specific receptor expressed by a target cell, including cancer cells, with a radioisotope.
RLT的工作原理是将靶向分子（配体）与放射性同位素结合，该分子与靶细胞（包括癌症细胞）表达的特定受体结合。
Bispecific antibodies can simultaneously bind two separate and unique antigens, which are protein molecules that can provoke an immune response and that are present on the surface of invading or cancerous cells.
双特异性抗体可以同时结合两种单独且独特的抗原，这两种抗原是可以引发免疫反应的蛋白质分子，存在于入侵或癌细胞的表面。
The company's more than 10 innovative molecules in discovery, with focus on innate immunity and tumor microenvironment, competed with an innovative antibody drug treating tumors.
It currently sells more than 200 varieties of hyaluronic acid with different specifications, and can produce products with the largest and smallest numbers of molecules in the world.
The company currently has a number of leading global innovative drug research projects ranging from anti-tumor, anti-infection, treatment of immune diseases and osteoarthritis to other areas, covering small molecule chemical medicine, traditional Chinese medicine and biological medicine.
OJESH, which specializes in small molecule hyaluronic acid skin care products, entered China, the world's second largest beauty market, in 2016.
Insilico Medicine, a global company in end-to-end artificial intelligence for target discovery, small molecule chemistry and clinical development, announced on Tuesday that it has raised $255 million in its series C financing led by Warburg Pincus.
Insilico Medicine demonstrated the first case of AI identifying a novel target for a major pulmonary disease, generating novel molecules for that novel target, and completing the preclinical experiments required to nominate a preclinical candidate in under 18 months.
Listed on the Hong Kong stock exchange last December, the clinical-stage biopharmaceutical company earned $12.8 million from molecule license fees and $1.1 million from technology out-license fees in, respectively.
Founded in Beijing in 2010 as a biotechnology company, BeiGene completed construction of a small molecule manufacturing facility in Suzhou of Jiangsu province in 2016 and the initial phase of a bio-manufacturing base in Guangzhou in 2019.
"Instead of developing new molecules and pushing the molecules through the clinical trials, we serve as a manufacturing and service partner of promising drug-owners, to help them scale their drug production and guide their discoveries through the clinical development process," he said.
Wu Xin, managing director of UCB China, said about five innovative molecules, including those treating autoimmune disease and osteoporosis, are scheduled by the company to be launched in the China market over the next five years.
At present, the center has started phase I clinical trials for four hepatitis B molecules of different mechanisms, together with several new mechanism projects in the preclinical stage of research.
As of September, the Shanghai center had filed 223 patent applications, including those involving seven molecules that have entered the clinical development stage in China and overseas.
One is for a commercial small molecule oral solid dosage and the other for a biologics pilot facility.
The selective small molecule inhibitor BGB-3245 was discovered by BeiGene's scientists and is currently in preclinical development.
ORIN1001 is an investigational first-in-class small molecule drug that has a novel molecular target, novel mechanism of action and a novel chemical structural class and identity.
Partnering with universities, startups and other research institutions, the company will use algorithms to explore thousands of possible pathway options for target molecules, said Steve Vermant, managing director of life science at Merck in China.
With its aid, chemists stand to analyze tens of thousands of pathways for known and novel molecules against different search criteria, which allows for testing what's probable without the hassle of conducting experiments.
"To take a molecule from that inception through all the development in the laboratory, through all the processes that you need to go through to actually test it in humans, it's been a hell of a ride! "
""So what this molecule that we've made does is it stops the tumor cells from metabolising the sugar in the way that they want and as a result, they can't divide and then if that block goes on for long enough they die.
The membrane separation technology is a filtration process to remove ions, molecules or larger particles from water, and is used in a variety of industries, including steel, desalination and power.
Vontron's main products currently use reverse osmosis, a water purification technology that uses a semipermeable membrane to remove ions, molecules and larger particles from drinking water.
People with the disorder produce either no or insufficient hemoglobin, the protein molecule in red blood cells that carries oxygen from the lungs to the body's tissues and returns carbon dioxide from the tissues to the lungs.
The drug maker has a global research team of over 2,000 scientists and 110 ongoing innovative drug projects, covering large molecules, small molecules, and new formulations, said Wang Zhenguo, executive director of the group.
Small molecule drugs, new types of vaccines and new-generation antibody drugs will be the major sectors that Shanghai's biopharmaceutical companies will focus on in the near future, according to attendees of the IBIWS.
It provides end-to-end process R&D and manufacturing services across small molecule active pharmaceutical ingredients or APIs, dosage forms and biologics to top multinational pharmaceutical companies as well as startups.
Compared with traditional methods of treating contaminated water, electron beam technology is safer and cleaner as well as more effective at removing organic molecules, said CGN Nuclear Technology Development Co, a subsidiary of China's state-owned nuclear power giant China General Nuclear Power Corp. As a project jointly conducted with Tsinghua University, the technology accelerates electrons to interact with molecules in the water to kill microorganisms and destroy viruses.
Currently in the preclinical stage, the molecule cross-links tumor cells and T cells by targeting a specific tumor-associated antigen and a protein complex and thus leads to potent T cell activation to fight the tumor.
A bispecific antibody is a molecule designed to recognize two different antigens or two different epitopes on the same antigen to treat tumors and other diseases and therefore is widely believed to have superior clinical therapeutic effects compared with traditional monoclonal antibodies.
Insilico Medicine, an end-to-end AI-driven drug discovery company with a key research and development team based in Shanghai, announced on Feb 24 it had dosed multiple healthy volunteers in the phase-1 clinical trial to evaluate the safety of ISM001-055, the first anti-fibrotic small molecule inhibitor generated by its AI-powered drug discovery platform for idiopathic pulmonary fibrosis.
A drug target is a molecule in the body, usually a protein, which is intrinsically associated with a particular disease process and could be addressed by a drug to produce a desired therapeutic effect.
The candidate compound is a potential first-in-class small molecule inhibitor, Insilico claims.
According to Wei Dong, CEO of EdiGene, biotech enterprises are growing rapidly in China and their focus is expanding to diverse domains－from small molecule and macromolecule to cell and gene therapies.
"China is now moving from developing so-called fast follower molecules to more novel technologies.
He said that Lilly and Innovent are also working on several other molecules in disease areas of oncology and immune oncology, and are looking for the next generation of PD-1 and PDL-1 with a goal of including two targets into one molecule.
One is Shenzhen TargetRx Inc, a biopharmaceutical company founded in 2014 focusing on developing international cutting-edge cancer drugs that block the growth and spread of tumors by interfering with specific molecules.
In addition, nine molecules, the development of which involved the innovation center, have entered clinical trial phases.
He and his team of scientists started by isolating some of the basic building blocks that give meat its delicious taste, like heme protein, a molecule that makes blood look red and helps give meat its chewy texture.
"Rapid technological improvements have allowed many Chinese labs to eliminate the presence of other elements that impact diamond quality, such as nitrogen molecules that make the stone look yellow and reduce its value," Sun said.
Instead of plastic surgery, "light medical aesthetics", which usually refers to nonsurgical treatment such as small molecule hyaluronic acid injections and thermage, or skin tightening, have become popular as they are cheaper and less risky.
"Dong Xiaoyin is a regular user of beauty booster injections of small molecule hyaluronic acid to keep her skin luminous and glowing.
In an article published on Henlius Biotech's WeChat account, Scott Liu, the company's president, CEO and co-founder, said biologics are structurally complex large molecules produced in living cells and more difficult to characterize than chemically synthesized small-molecule drugs.
The company is also teaming up with another institute which has been working on the coronavirus for over 10 years to develop a new small molecule specific drug for COVID-19.
Wai Keong Tang, director of the think tank committee of Macao Youth Association of Patriotic Education, said: "AI shortens the time of finding the target drug, as AI algorithms allow developers to quickly spot the best drug candidate for a target or molecular compounds of subsequent drug candidates, including protein sequence, molecular structure, and small molecule composition among others.
Shenzhen-based small molecule innovative medicines maker Chipscreen Biosciences, semiconductor material provider Anji Microelectronics (Shanghai) Co Ltd and Suzhou-based machine vision technology provider TZTEK saw their applications go public on the new tech board approved at a review conference on Friday as scheduled.